[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anorexia-nervosa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anorexia-nervosa":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,97,0,25,[9,44,74,94,116,144,172,193,238,273,297,327,348,369,388,415,436,463,488,516,541,561,584,605,631],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100652428","identifying-multidimensional-signatures-of-gastric-interoception-in-functional-dyspepsia-100652428",false,"NCT07772167","Identifying Multidimensional Signatures of Gastric Interoception in Functional Dyspepsia","IMAGINE","Participant Inclusion Criteria--\n\nFunctional Dyspepsia Group:\n\n* Males and females; ages 18-65 years\n* Rome V functional dyspepsia post-prandial distress syndrome subtype\n* Negative upper endoscopy or upper GI series to rule out structural\u002Forganic cause for FD\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Fluent in English\n* Willing and able to provide informed consent\n* Stable dose for 30 days prior to Visit 1 if on a neuropsychiatric medication (e.g., TCA, SNRI, SSRI mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)\n* No current plans to initiate a new or change dosing on a neuropsychiatric medication within the study period\n\nAnorexia Nervosa Group:\n\n* Males and females; ages 18-65 years\n* DSM-5 anorexia restricting-type by the Eating Disorder Module in the Diagnostic Interview for Mood, Anxiety, and OCD and related Neuropsychiatric Disorders (DIAMOND)\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Fluent in English\n* Willing and able to provide informed consent\n* Stable dose for 30 days prior to Visit 1 if on an SSRI\n* No current plans to initiate a new neuromodulator\n* No current plans to initiate a new SSRI or change dosing on an SSRI\n\nHealthy Controls:\n\n* Males and females; ages 18-65 years\n* BMI greater than or equal to 18.5 kg\u002Fm2\n* Fluent in English\n* Willing and able to provide informed consent\n\nParticipant Exclusion Criteria--\n\nFunctional Dyspepsia Group:\n\n* Presence of other conditions that could explain the patient's symptoms by medical chart:\n\n  * Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT)\n  * Active H.pylori (by CLO test or stool antigen test)\n  * Active inflammatory bowel disease\n  * Eosinophilic gastroenteritis or eosinophilic esophagitis\n  * Acute renal failure\n  * Chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis\n  * Acute liver failure\n  * Any acute gastrointestinal process\n  * Any plausible structural or metabolic causes\n  * Heartburn as predominant symptom\n  * History of peptic ulcer\n* Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* History of weight\u002Fshape-based eating disorder including anorexia nervosa by DIAMOND\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by modified DIAMOND abbreviated suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent\n\nAnorexia Nervosa Group:\n\n* Diagnosis of chronic gastrointestinal disorder\n* Rome V functional dyspepsia\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by DIAMOND abbreviated suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent\n* Current use of neuropsychiatric medication other than an SSRI (e.g., TCA, SNRI, mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)\n\nHealthy Controls:\n\n* Diagnosis of chronic gastrointestinal or pain disorder\n* Rome V functional dyspepsia\n* greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)\n* Current use of a medication known to influence gastric sensorimotor functions (including neuromodulators and SSRIs)\n* Active psychiatric disorder including a feeding\u002Feating disorder by DIAMOND\n* Endorses any contraindications to MRI\n* Body weight of 450 lbs or greater or BMI of 50 kg\u002Fm2 or greater (limit of MRI table)\n* Allergy to pineapple (used in the test meal during MRI)\n* History of GI tract surgery or any serious medical condition (e.g., cancer)\n* Pregnancy\u002Fbreastfeeding within the last 8 weeks\n* Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart\n* Narcotic analgesics greater than three days per week\n* Cannabinoid use greater than three days per week\n* Intellectual disability by history\n* Illiteracy\n* Current binge eating by DIAMOND\n* Current self-induced vomiting by DIAMOND\n* Current laxative or diuretic misuse by DIAMOND\n* Current substance\u002Falcohol use disorder within past year by DIAMOND\n* Current\u002Fhistory of psychosis by DIAMOND\n* Current mania by DIAMOND\n* Active suicidal ideation by DIAMOND modified suicide module; passive suicidal ideation is allowed\n* Inability or unwillingness to consume food by mouth\n* Inability to provide informed consent",true,"ALL","18 Years","65 Years",{"count":22,"type":23},150,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is being conducted to investigate gut-brain communication in individuals with functional dyspepsia and anorexia nervosa. The hope is that what the investigators learn from this study will improve the understanding the conditions better to improve treatments.",[29,30],"Functional Dyspepsia","Anorexia Nervosa","RECRUITING","2026-08-14",{"date":34,"type":35},"2026-08-19","ACTUAL",{"date":37,"type":35},"2026-03-16",{"date":39,"type":23},"2031-03",{"name":41,"class":42},"Massachusetts General Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100605992","phase-2-safety-therapeutic-potential-and-mechanisms-of-two-psilocybin-doses-administered-with-psychological-support-in-young-adults-with-anorexia-nervosa-100605992","NCT07169747","Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa","The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults","psiAN","Inclusion Criteria:\n\n* Diagnosis of AN per DSM-5, including anorexia nervosa in partial remission.\n* Have experienced at least one period of weight restoration to a minimum BMI of 17 followed by subsequent weight loss.\n* Age 16-35\n* BMI \\>16\n* Stable contact with a psychiatric unit\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Psychosis, bipolar disorder, substance use disorder, family history of psychosis or bipolar disorder, refusal of birth control, lifetime psychedelic use.\n* Cardiovascular conditions\n* Resting systolic blood pressure \\>140 mmHg or diastolic blood pressure \\>90 mmHg at screening or baseline\n* Clinically significant arrhythmias, tachycardia and QT prolongation\n* History of stroke, myocardial infarction, or other significant cardiovascular events\n* Seizure disorders or history of epilepsy\n* Diabetes mellitus, positive drug tests, suicidal intent, allergy or intolerance to drug content, blood or needle phobia\n* Only for the MRI-part of the study: Metal pieces in the body (contraindicated by fMRI, assessed in each case by MR-technician). Non-compliance to fMRI will not lead to study exclusion\n* Any other clinically significant medical condition that, in the investigator's opinion, may pose a risk to the participant or interfere with study results\n* Care under the Swedish Compulsory Psychiatric Care Act (LPT)\n* Ongoing treatment with medications that have clinically relevant 5-HT2A-receptor antagonistic properties and are therefore expected to directly block or substantially interfere with the pharmacodynamic effects of psilocybin. Such medications require an appropriate washout period prior to psilocybin administration, based on pharmacokinetic properties and clinical judgement. Medications without direct 5-HT2A-antagonistic effects are not excluded on this basis.\n* BMI \\> 21.0 for ≥ 6 consecutive months within the 12 months prior to screening, as documented in medical records.","16 Years","35 Years",{"count":55,"type":23},40,[57],"PHASE2","The goal of this clinical trial is to learn if psilocybin, given with psychological support, is safe and helps treat anorexia nervosa in young adults. Anorexia nervosa is a serious eating disorder that currently has no approved medicine. Psilocybin is a psychedelic substance that may help the brain form new connections, which could make it easier for people with anorexia nervosa to develop healthier ways of thinking.\n\nThe main questions this study aims to answer are:\n\n* Is psilocybin with psychological support safe and well-tolerated?\n* Does psilocybin with psychological support help lower symptoms of anorexia nervosa?\n* How might psilocybin work in the brain to support recovery from anorexia?\n\nThis study will compare psilocybin with psychological support to Treatment as Usual (TAU). Participants in the study will be randomly placed into one of the two groups. There will be 40 patients with anorexia nervosa included, 20 per group. TAU includes the standard care people receive for anorexia nervosa in a specialized eating disorder clinic in Region Skåne, Sweden.\n\nParticipants will:\n\n* Be between 16 and 35 years old and have anorexia nervosa\n* Take psilocybin (25 mg) by mouth two times, four weeks apart\n* Receive psychological support before, during, and after each dosing session (including preparation and integration sessions)\n* Complete questionnaires, have brain scans (magnetic resonance imaging) and blood tests to learn more about how psilocybin may work\n* Share their personal experiences as part of a qualitative interview\n\nThis study hopes to learn if psilocybin, when given with the right support, can be a helpful and safe option for people living with anorexia nervosa.",[30],[61,30,62,63,64,65],"Psilocybin","Young adults","fMRI","BDNF","Adolescents","2026-08-12",{"date":32,"type":35},{"date":69,"type":23},"2026-07-20",{"date":71,"type":23},"2027-10-01",{"name":73,"class":42},"Region Skane",{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":43},"100500716","neuroscience-informed-treatment-to-remotely-target-reward-mechanisms-in-post-acute-anorexia-nervosa-100500716","NCT05799872","Neuroscience-informed Treatment to Remotely Target Reward Mechanisms in Post-acute Anorexia Nervosa","Inclusion Criteria:\n\n1. Age \\> or = 18 years old\n2. Ability to read and speak in English\n3. DSM-5 diagnosis of AN or atypical AN at admission to higher-level care\n4. In higher-level care discharging to outpatient care or discharged to outpatient care within the past 3 months\n5. Current BMI \\> or = 18.5 kg\u002Fm2 (or will be by time of discharge)\n6. BMI increase of \\> or = 0.5 kg\u002Fm2 while in higher-level care\n7. Ability to designate and sign a release of information for a primary physical or mental health provider for study duration\n8. Willingness to participate in weekly assessments (e.g., weight monitoring) and audio or video recording of study therapy sessions for study duration\n9. Access to a smartphone and\u002For computer permitting engagement in remote therapy and assessment.\n\nExclusion Criteria:\n\n1. Medical instability for outpatient care;\n2. Pregnancy\n3. Lifetime DSM-5 primary psychotic or bipolar-I disorder\n4. Current DSM-5 substance use disorder\n5. Enrollment in outpatient therapy with highly overlapping content to PAT-AN",{"count":81,"type":23},90,[26],"The investigators will recruit individuals with broadly-defined AN (n = 80) who are currently in or have recently participated in higher-level eating disorder treatment (e.g., residential, partial hospitalization\u002Fday treatment, intensive outpatient treatment). Interested participants will sign consent, complete eligibility assessments, and will be randomized to receive Positive Affect Treatment for Anorexia Nervosa (PAT-AN) or Psychoeducation and Behavioral Therapy (PBT) through teletherapy shortly following discharge from higher level of care. Participants can participate in most other forms of outpatient treatment while receiving the research intervention. Participants will engage in 24 weeks of PAT-AN or PBT starting in the first 3 months post-discharge. At each session, the investigators will complete brief measures assessing treatment acceptability, affect, and eating disorder symptoms. Participants will also complete an assessment battery of self-report, EMA, and neurocognitive measures evaluating primary outcomes (BMI; eating disorder symptoms), secondary outcomes (depression, anxiety, and suicidality), and presumed treatment mechanisms at baseline, end of treatment (EOT), and 3-month follow-up (FU). All assessments will be remotely delivered via HIPAA-compliant platforms.",[30],"2026-08-10",{"date":87,"type":35},"2026-08-11",{"date":89,"type":35},"2023-12-06",{"date":91,"type":23},"2026-08-31",{"name":93,"class":42},"Virginia Commonwealth University",{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":18,"minAge":52,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":24,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":43},"100638768","incorporating-narrative-into-the-treatment-of-youth-with-anorexia-nervosa-virtual-100638768","NCT07579442","Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)","Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa","Inclusion Criteria:\n\n* 16-25 years old\n* have a DSM-5 diagnosis of AN (confirmed by the UCSF Eating Disorders Program clinical team),\n* currently engaged in outpatient eating disorder treatment, ensuring medical stability and capacity for a group-based intervention\n* English fluency to engage in reflective writing and discussions\n* Cognitive ability to meaningfully participate in narrative-based exercises\n\nExclusion Criteria:\n\n* Currently medically unstable or require inpatient hospitalization\n* History of psychosis, schizophrenia spectrum disorder, bipolar disorder, or personality disorder\n* Severe neurocognitive impairment that would prevent engagement with the intervention\n* Active suicidal ideation or non-suicidal self-injury within the past two months\n* Insufficient English proficiency to participate in group discussions and writing exercises","25 Years",{"count":103,"type":23},10,[26],"The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.\n\nThe main questions it aims to answer are:\n\n* Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa?\n* Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?\n\nParticipants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.\n\nParticipants will:\n\n* Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility\n* Engage in close reading of visual or written texts\n* Complete creative writing exercises in response to prompts\n* Participate in group discussions and sharing\n\nAn optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.\n\nThis study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.",[30],"NOT_YET_RECRUITING","2026-08-07",{"date":87,"type":35},{"date":111,"type":23},"2026-08-15",{"date":113,"type":23},"2027-07-01",{"name":115,"class":42},"University of California, San Francisco",{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":24,"phases":124,"briefSummary":125,"conditions":126,"keywords":127,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":43},"100555965","phase-2-an-open-trial-of-a-novel-pharmacotherapy-for-habit-modification-in-anorexia-nervosa-100555965","NCT06518941","An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study (Clinical interview).\n3. Aged 18-60 years (Clinical interview).\n4. Diagnosed with anorexia nervosa (EDA-5).\n5. BMI ≥ 15 kg\u002Fm2 (Clinical team medical record)\n\nExclusion Criteria:\n\n1. Score of High Risk on the Columbia Suicide Severity Scale (C-SSRS).\n2. Pregnancy (Serum pregnancy test on admission).\n3. Current diagnosis of schizophrenia, schizophreniform disorder, bipolar (type I), or substance use disorder (SCID).\n4. Bradycardia (below 60 bpm) (vital signs measurement by the clinical team)\n5. Corrected QT interval (QTc) greater than 480 ms at baseline (EKG).\n6. Antipsychotic medication (antidepressants at a stable dose are allowed) (clinical interview).\n7. Known allergic reactions to components of the donepezil (e.g., known hypersensitivity to donepezil hydrochloride) (clinical interview).\n8. History of peptic ulcer disease (clinical interview).\n9. History of arrhythmia (clinical interview).","60 Years",{"count":103,"type":23},[57],"The purpose of this study is to test the feasibility and tolerability of donepezil in a small group of patients with anorexia nervosa (AN). Study participants will be receiving care at the New York State Psychiatric Institute Eating Disorders Unit. Study medication will be increased from 1 mg per day to a maximum of 5 mg per day for up to 8 weeks. Participants will be closely monitored for side effects by a research psychiatrist every week, in addition to the regular clinical monitoring they receive during inpatient treatment. The study will also include assessments of habit strength to measure any changes in maladaptive eating habits over the course of the treatment.",[30],[128,129,130,131,132,133,134],"anorexia","anorexia nervosa","donepezil","eating disorders","acetylcholinesterase inhibitor","Acetylcholine","habit","2026-07-30",{"date":137,"type":35},"2026-08-03",{"date":139,"type":23},"2027-01",{"date":141,"type":23},"2028-12",{"name":143,"class":42},"New York State Psychiatric Institute",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":152,"maxAge":20,"enrollmentInfo":153,"targetDuration":4,"studyType":24,"phases":155,"briefSummary":156,"conditions":157,"keywords":158,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":43},"100539541","phase-2-metreleptin-in-anorexia-nervosa-100539541","NCT06305182","Metreleptin in Anorexia Nervosa","Metreleptin in Anorexia Nervosa, Randomized Controlled Trial; Effects on Depressive Symptoms and Concomitant Changes in Brain Connectivity","METRAN","Main key inclusion criteria:\n\n* Current diagnosis of AN according to fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) confirmed with Structured Clinical Interview for DSM-5 (SCID-5)\n* BMI \\> 13 kg\u002Fm2; BMI ≤ 18 kg\u002Fm2; body weight ≥ 35 kg\n* Hospitalisation in the Eating Disorders Unit, Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital of Zurich\n* Ability to understand German language\n* Age range: 17 - 65 years\n* Depressive symptoms: HAMD-17 ≥ 8\n* Negative urine pregnancy test, non-lactating and double birth control\n* Informed Consent as documented by signature\n\nMain key exclusion criteria:\n\n* Illicit drug intake within last month; current alcohol use disorder\n* Severe psychiatric and\u002For severe somatic comorbidities; f. e. lifetime diagnosis of schizophrenia, bipolar disorder, inflammatory bowel disorders, diabetes mellitus, autoimmune disorders, pancreatitis, neurological disorders, cancer including lymphoma\n* Acute suicidality or current serious non-suicidal self-injury","17 Years",{"count":154,"type":23},50,[57],"The treatment of anorexia nervosa often proves to be difficult. There are no drugs that work specifically for the treatment of anorexia nervosa. Experimental administration of metreleptin (synthetically produced leptin) to patients with anorexia nervosa has produced positive results. This study tests the effect of metreleptin in comparison with placebo, which could potentially make treatment easier. The aim of the study is to investigate whether treatment with metreleptin can help to reduce the symptoms of anorexia nervosa and improve mood and weight.",[30],[30,159,160,161,162],"Leptin","Metreleptin","Weight gain","Depression","2026-07-28",{"date":165,"type":35},"2026-07-29",{"date":167,"type":35},"2024-05-31",{"date":169,"type":23},"2026-12-31",{"name":171,"class":42},"Gabriella Milos",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":24,"phases":181,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":43},"100649299","online-fbt-dbt-caregiver-intervention-for-caregivers-of-individuals-with-anorexia-nervosa-100649299","NCT07734779","Online FBT-DBT Caregiver Intervention for Caregivers of Individuals With Anorexia Nervosa","A Randomized Controlled Trial of an Online Family-Based Treatment (FBT) Combined With Dialectical Behavior Therapy (DBT) Intervention Versus Online Supportive Psychological Intervention for Reducing Caregiver Burden Among Caregivers of Individuals With Anorexia Nervosa","Inclusion Criteria:\n\n* Primary caregiver of an individual diagnosed with anorexia nervosa (AN) by a qualified clinician.\n\nThe individual with AN is between 10 and 18 years of age. The individual with AN does not have a severe comorbid physical illness or severe psychiatric disorder.\n\nThe caregiver lives in the same household as the individual with AN. The caregiver has at least a primary school level of education and is able to complete study procedures and questionnaires.\n\nAll participating caregivers from the same family are willing to participate in the intervention and assessment procedures.\n\nAble and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Currently providing care for another family member with a chronic physical illness or psychiatric disorder.\n\nCurrent or past history of a severe physical illness or severe psychiatric disorder that would interfere with study participation.\n\nSevere emotional instability, active self-harm or suicidal behavior, psychotic symptoms, or other psychiatric conditions requiring immediate clinical intervention.\n\nUnable or unwilling to participate in the intervention or assessment procedures.",{"count":180,"type":23},100,[26],"Anorexia nervosa (AN) is a severe psychiatric disorder characterized by a chronic and relapsing course. Caregivers of individuals with AN often experience substantial caregiving burden, emotional distress, and impairment in family functioning due to their ongoing responsibilities in meal supervision, treatment support, and symptom management. Despite the critical role of caregivers in treatment and recovery, evidence-based interventions specifically targeting caregiver burden remain limited in China.\n\nThis study aims to develop and evaluate an online intervention integrating Family-Based Treatment (FBT) and Dialectical Behavior Therapy (DBT) for caregivers of individuals with AN. FBT emphasizes empowering caregivers to support nutritional rehabilitation and recovery, whereas DBT provides skills in emotion regulation, validation, and effective communication. The integration of these approaches may help caregivers reduce distress, improve caregiving skills, and enhance family functioning.\n\nThis study will employ a randomized controlled trial design. A total of 80 primary caregivers of individuals with AN will be recruited and randomly assigned to either an online FBT-DBT intervention group or an online supportive psychological intervention group. Both interventions will be delivered in a group format over 12 weeks. Assessments will be conducted at baseline, 4 weeks, 8 weeks, post-intervention (12 weeks), and at 1-month and 3-month follow-up. The primary outcome will be caregiver burden. Secondary outcomes will include psychological distress, negative emotional experiences, and the impact of eating disorder symptoms on the family.\n\nThe study aims to determine the effectiveness of the online FBT-DBT intervention in reducing caregiver burden and psychological distress and to evaluate whether it provides greater benefits than supportive psychological intervention. Findings may contribute to the development of accessible and evidence-based caregiver interventions for families affected by AN in China.",[30,184],"Caregiver Burden","2026-07-24",{"date":165,"type":35},{"date":188,"type":35},"2026-04-03",{"date":190,"type":23},"2027-01-20",{"name":192,"class":42},"Shanghai Mental Health Center",{"id":194,"slug":195,"hasResults":12,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":204,"conditions":205,"keywords":215,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":234,"leadSponsor":236,"locationsCount":237},"100648767","3-dimensional-optical-scanning-to-assess-and-monitor-malnutrition-in-eating-disorders-3d-ed-study-100648767","NCT07726524","3-Dimensional Optical Scanning to Assess and Monitor Malnutrition in Eating Disorders (3D-ED) Study","3D-ED","Inclusion Criteria:\n\n* Diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (AAN), restricting or purging subtype, per DSM-5\n* Age 15 to 26 years\n* Medical instability warranting an inpatient hospitalization defined by either:\n\n  1. vital signs: daytime heart rate below 50 bpm or nighttime heart rate below 45 bpm, blood pressure below 90\u002F50 mm Hg, temperature below 36 C, orthostatic increase in heart rate above 20 bpm or decrease in systolic blood pressure above 20 mm Hg or decrease in diastolic blood pressure above 10 mm Hg from lying to standing, or median BMI below 75 percent; or\n  2. laboratory abnormality: AST above 40 IU\u002FL, ALT above 30 IU\u002FL, estimated GFR below 90 or cystatin C below 0.7 mg\u002FL, albumin below 3.7 g\u002FdL, or prealbumin below 20 mg\u002FdL\n* Extreme AN is defined as BMI below 15 kg\u002Fm2 or serious medical complications warranting admission to ACUTE (Denver Site).\n\nExclusion Criteria:\n\n* Bulimia nervosa\n* Another primary diagnosis causing malnutrition (not an eating disorder)\n* Current active suicidality\n* Metal implants or devices that interfere with study procedures","15 Years","26 Years",{"count":81,"type":23},"OBSERVATIONAL","People with anorexia nervosa often become medically unstable because of severe malnutrition and require hospitalization for nutritional rehabilitation. Clinicians currently rely heavily on body weight to assess malnutrition, but body weight does not always reflect the severity of illness. This study will use infrared scanning to assess body composition in adolescents and young adults hospitalized with anorexia nervosa. Researchers will then examine how organ and tissue stores relate to the degree of malnutrition, predict nutritional needs and medical restoration in hospital, and recovery outcomes over the following year. The goal is to develop more individualized approaches to nutritional rehabilitation and improve recovery for individuals with malnutrition due to eating disorders.",[206,30,207,208,209,210,211,212,213,214],"Anorexia in Adolescence","Anorexia Nervosa, Atypical","Anorexia Nervosa, Binge Eating\u002FPurging Type","Anorexia Nervosa Restricting Type","Anorexia Nervosa With Significantly Low Body Weight","Body Composition Changes","Growth & Development","Malnutrition Severe","Malnutrition, Calorie",[216,217,218,219,220,221,222,223,224,225,226,227,228,229,230],"Organ residual mass","Body composition","Three-dimensional optical imaging","Optical body scanning","Refeeding","Refeeding syndrome","Nutritional rehabilitation","Resting energy expenditure","Eating disorders","Bioelectrical impedance analysis","Fat-free mass","Adolescent","Young adult","Anorexia nervosa","Growth charts","2026-07-22",{"date":185,"type":35},{"date":139,"type":23},{"date":235,"type":23},"2031-05",{"name":115,"class":42},2,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":24,"phases":249,"briefSummary":250,"conditions":251,"keywords":256,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":43},"100639845","eating-disorder-dynamic-intervention-100639845","NCT07600671","Eating Disorder Dynamic Intervention","Rapid Innovation of Precision Psychiatry Interventions Using Dynamic Systems Modeling and Ecological Quasi-Experiments","EDDI","Inclusion Criteria:\n\n1. Age 18-70\n2. At least 12 ED behaviors from the same behavioral category in the past 12 weeks (i.e., at least 12 binge eating episodes, at least 12 compensatory behaviors, and\u002For at least 12 instances of dietary restriction)\n3. Ownership of a smartphone\n4. Willingness to complete ecological momentary assessment (EMA) and sensor data collection\n5. Live in the United States\n6. Has a primary care provider or is willing to establish a primary care provider\n\nExclusion Criteria:\n\n1. Inability to fluently speak, read, and write in English\n2. Body mass index \\\u003C 17.5 kg\u002Fm2\n3. Medical complications of ED symptoms requiring immediate treatment\n4. Current ED-focused therapy\n5. Severe psychopathology (i.e., active suicidal ideation, psychosis, bipolar disorder, or substance use disorder) or intellectual disability inhibiting engagement in study protocols","70 Years",{"count":248,"type":23},170,[26],"The goal of this study is to develop and test a digital program to help people with eating disorders in their everyday lives. The program uses brief surveys and sensor data collected by smartphones to understand when someone may be at higher risk for behaviors like restricting food, binge eating, or using unhealthy weight control behaviors.",[252,30,253,254,255],"Eating Disorders","Bulimia Nervosa","Binge Eating Disorder","Other Specified Feeding or Eating Disorder",[257,258,259,260,261,262,263],"binge eating","eating problem","eating disorder","purging","restriction","weight control behavior","dieting","2026-07-15",{"date":266,"type":35},"2026-07-16",{"date":268,"type":35},"2026-07-08",{"date":270,"type":23},"2030-07-31",{"name":272,"class":42},"Trustees of Dartmouth College",{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":12,"sex":280,"minAge":19,"maxAge":53,"enrollmentInfo":281,"targetDuration":4,"studyType":24,"phases":283,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":43},"100509853","effects-of-rtms-on-food-choice-in-anorexia-nervosa-100509853","NCT05918835","Effects of rTMS on Food Choice in Anorexia Nervosa","Deciphering the Neural Mechanisms of Restrictive Eating in Anorexia Nervosa Using Repetitive Transcranial Magnetic Stimulation","Inclusion Criteria:\n\n* DSM-5 Diagnosis of Anorexia Nervosa\n* Age 18-35 years\n* Female\n* Right-handed\n* Body Mass Index (BMI) ≥ 16.0\n* Voluntarily admitted to inpatient eating disorders unit at NYSPI\n* Competent to provide informed consent\n* English-speaking\n* Medically stable\n\nExclusion Criteria:\n\n* High risk of suicide\n* Current substance use disorder or other co- morbid psychiatric condition requiring specialized treatment (e.g., psychosis)\n* Diagnosis of major medical or neurological problem or taking medication that significantly increases risk for seizure or affects interpretation of findings (e.g., unstable hypertension, seizure disorder)\n* Food restrictions (e.g., allergies) which impact greater than 30% of food choice task's choice options\n* Indwelling ferromagnetic metallic object (e.g., pacemaker, pump), non- removable metal jewelry, medicinal patch or recent metallic ink tattoo\n* History of seizure\n* Diagnosis of epilepsy, stroke, multiple sclerosis, traumatic brain injury, Alzheimer's and other neurodegenerative diseases, meningoencephalitis or intracerebral abscess, or parenchymal or leptomeningeal cancers\n* Prior exposure to TMS\n* Pregnancy\n* Currently breast-feeding\n* Significant claustrophobia\n* Implanted devices or stimulators\n* Hearing loss (e.g., currently undergoing treatment with ototoxic medications or those with cochlear implants)","FEMALE",{"count":282,"type":23},72,[26],"This study will examine the impact of high-frequency repetitive transcranial magnetic stimulation on food choice behavior and related neural activity.",[30],[287,30,288,289],"Repetitive Transcranial Magnetic Stimulation","Restrictive Eating","Feeding and Eating Disorders","2026-07-13",{"date":264,"type":35},{"date":293,"type":35},"2023-04-24",{"date":295,"type":23},"2027-06-30",{"name":143,"class":42},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":17,"sex":18,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100561803","eating-disorders-genetics-initiative-2-100561803","NCT06594913","Eating Disorders Genetics Initiative 2","EDGI2","Inclusion Criteria:\n\n* A lifetime history of anorexia nervosa, bulimia nervosa, binge-eating disorder, avoidant restrictive food intake disorders or no history of any disordered eating behavior, based on DSM-5 criteria algorithms\n* Age 12-99 years, depending on country. (US enrollment age is 18-99)\n\nExclusion Criteria:\n\n* History of subthreshold disordered eating behaviors.","12 Years","99 Years",{"count":307,"type":23},20000,"The overarching intention of the Eating Disorder Genetics Initiative 2 (EDGI2) is to increase sample size, diversity, and eating disorder phenotypes. The investigators are enrolling 20,000 new participants with anorexia nervosa (AN), bulimia nervosa (BN), binge-eating disorder (BED), avoidant\u002Frestrictive food intake disorder (ARFID), and controls in the US, Mexico, Australia, New Zealand, Sweden, and Denmark. A primary study goal is to enroll at least 30% of participants from underrepresented groups. Participants are asked to complete a series of questionnaires and submit a saliva sample for genotyping. The goal is to better understand eating disorders and how they relate to each other so that better treatments can be developed.",[30,253,310,311],"Binge-Eating Disorder","Avoidant Restrictive Food Intake Disorder",[313,314,315,316,317],"severe and enduring eating disorder","genetics","mental health","disordered eating","environmental factors","2026-07-06",{"date":268,"type":35},{"date":321,"type":35},"2024-10-28",{"date":323,"type":23},"2027-09-01",{"name":325,"class":42},"University of North Carolina, Chapel Hill",5,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":17,"sex":18,"minAge":52,"maxAge":334,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":43},"100646340","biasing-food-value-construction-100646340","NCT07692945","Biasing Food Value Construction","Constructing the Subjective Value of Food in Anorexia Nervosa","Inclusion Criteria:\n\n* aged 16-35 years\n* male or female\n* able to read and speak English\n\nExclusion Criteria for all participants:\n\n* history of concussion or neurological disease\n* full scale IQ estimate \\\u003C 80;\n* taking medication that has been shown to affect attention or learning (i.e., second generation antipsychotics, memantine, methylphenidate, or modafinil)\n\nExclusion Criteria for participants with anorexia nervosa:\n\n* current psychosis, bipolar disorder, or substance dependence\n* body mass index \\\u003C 14\n* vital sign or laboratory abnormalities indicating medical instability","45 Years",{"count":22,"type":23},[26],"The goal of this clinical trial is to examine whether food value construction can be biased in individuals with anorexia nervosa. The main question it aims to answer is:\n\nCan a simple training task increase the importance of relevant food attributes such that subsequent choices about what to eat in individuals with anorexia nervosa will look more like those of healthy eaters?\n\nParticipants will undergo a simple training paradigm where they view food items and focus on different attributes (e.g., its tastiness or healthiness). Participants will then be asked to make decisions about what foods they'd like to eat.",[30],"2026-07-02",{"date":341,"type":35},"2026-07-09",{"date":343,"type":23},"2026-09-01",{"date":345,"type":23},"2028-07-31",{"name":347,"class":42},"University of Chicago",{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":18,"minAge":304,"maxAge":19,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":43},"100497945","interoceptive-exposure-for-adolescents-with-low-weight-eating-disorders-100497945","NCT05763849","Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","A Confirmatory Efficacy Study of Interoceptive Exposure for Adolescents With Low Weight Eating Disorders","Inclusion Criteria:\n\n* Aged 12-18\n* Speak English\n* Permission from pediatrician or equivalent to receive outpatient care\n* Clinically significant restriction of food intake by EDA-5 or evidence of persistent food avoidance from patient or guardians\n* Evidence of the inability to maintain greater than minimally low body weight based on BMI for age percentiles and growth trajectories\n\nExclusion Criteria:\n\n* Comorbid psychotic or bipolar disorder\n* Active suicidal ideation\n* Current substance dependence\n* Psychiatric medication initiated or dosage changes \\\u003C2 weeks from baseline\n* Major medical illness (e.g., diabetes mellitus, Crohn's disease, etc.)",{"count":356,"type":23},120,[26],"This project includes a parallel group randomized controlled trial comparing two psychological treatments: 1) Exposure-based Family Therapy (IE) vs. 2) Family Based Therapy (FBT) for low weight eating disorders with 12 month follow-up. Primary outcomes are expected body weight and clinical impairment. Three mechanisms of change (Autonomous Eating, Non-Judgmental Body Awareness, and Extinction Learning) will be examined in a process mediation models of change.",[30],"2026-06-17",{"date":362,"type":35},"2026-06-22",{"date":364,"type":35},"2023-03-14",{"date":366,"type":23},"2028-01",{"name":368,"class":42},"Icahn School of Medicine at Mount Sinai",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":4},"100619907","inpatient-care-of-patients-with-difficult-to-treat-anorexia-nervosa---factors-affecting-treatment-outcome-100619907","NCT07350720","Inpatient Care of Patients With Difficult to Treat Anorexia Nervosa - Factors Affecting Treatment Outcome.","Inpatient Care of Patients With Difficult to Treat Eating Disorders - What Affects Treatment Outcome?","Inclusion Criteria:\n\n* Anorexia Nervosa diagnosis (ICD F50.0)\n* Admitted to inpatient care at department 5 at Region Skåne Eating Disorders Center\n\nExclusion Criteria:\n\n* Confidential identity\n* Inability to read or write in Swedish or English\n* Condition or treatment that, according to the study team, makes participation in the study inappropriate","64 Years",{"count":180,"type":23},"The overall aim of the project is to investigate factors that may influence treatment outcomes in people with difficult-to-treat anorexia nervosa who are enrolled in inpatient care at the Region Skåne Eating Disorders Centre in Lund. Treatment expectations, sense of autonomy, and patient participation, will be investigated, as well as caregivers' attitudes towards, and experiences of working with, autonomy and patient participation in the inpatient setting. The research project is expected to contribute to increased knowledge about the treatment of difficult-to-treat anorexia nervosa, and what part patient participation and autonomy may play when treating severe eating disorders. The overall objectives of the research program are:\n\n1. To contribute to increased knowledge about factors that influence the treatment of people with difficult-to-treat anorexia nervosa\n2. To highlight the role of autonomy and patient participation in inpatient care of severe eating disorders\n3. To use the research results for clinical improvement work at Region Skåne Eating Disorders Center",[252,30],"2026-06-15",{"date":382,"type":35},"2026-06-16",{"date":384,"type":23},"2026-09",{"date":386,"type":23},"2029-12",{"name":73,"class":42},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":280,"minAge":395,"maxAge":19,"enrollmentInfo":396,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":4},"100642373","sleep-quality-and-biomarkers-in-adolescent-girls-with-anorexia-nervosa-100642373","NCT07644728","Sleep Quality and Biomarkers in Adolescent Girls With Anorexia Nervosa","Sleep Architecture, Inflammatory and Hormonal Biomarkers, Psychopathology, and Quality of Life in Adolescent Girls With Anorexia Nervosa: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Female sex assigned at birth\n2. Age between 10 and 18 years (inclusive) at the time of study enrollment\n3. First-time diagnosis of anorexia nervosa according to ICD-10 criteria at the time of enrollment, including:\n\n   * Anorexia nervosa (F50.0)\n   * Atypical anorexia nervosa (F50.1)\n   * Eating disorder, unspecified (F50.9) with predominant restrictive or anorexic presentation\n4. Currently under the care of a child and adolescent psychiatrist at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia\n5. Enrolled in or eligible for the Day Hospital Program for Children and Adolescents at the Department of Psychiatry, KBC Split\n6. Ability to read and understand Croatian language sufficiently to complete self-report questionnaires\n7. Parent or legal guardian willing and able to provide written informed consent prior to any study procedure\n8. Participant willing and able to provide written assent prior to any study procedure\n9. Participant and parent\u002Fguardian willing to undergo all study procedures at both time points, including:\n\n   * Home polysomnography (NOX A1) at baseline and 12-month follow-up\n   * Completion of all self-report questionnaires at baseline and 12-month follow-up\n   * Fasting blood sampling at baseline and 12-month follow-up\n\nExclusion Criteria:\n\n1. Age younger than 10 years or older than 18 years at the time of enrollment\n2. Male sex assigned at birth\n3. Previous diagnosis of anorexia nervosa prior to current enrollment (i.e., recurrent or relapsing AN - this study enrolls first-diagnosis cases only)\n4. Anorexia nervosa currently in clinical remission at the time of enrollment\n5. Comorbid psychiatric diagnosis of any of the following:\n\n   * Intellectual disability (any severity, ICD-10: F70-F79)\n   * Autism spectrum disorder (ICD-10: F84)\n   * Schizophrenia spectrum or other psychotic disorder (ICD-10: F20-F29)\n   * Bipolar affective disorder, any type (ICD-10: F31)\n   * Substance use disorder, any substance (ICD-10: F10-F19)\n6. Severe or chronic somatic illness documented in medical history, including but not limited to:\n\n   * Central nervous system disorders (epilepsy, acquired brain injury, neurodegenerative disease, ICD-10: G00-G99)\n   * Chronic inflammatory or autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis)\n   * Primary endocrine disorder independent of AN (e.g., primary hypothyroidism, type 1 or type 2 diabetes mellitus, congenital adrenal hyperplasia)\n   * Active or history of malignancy\n   * Chronic renal or hepatic disease\n7. Use of any medication known to significantly alter sleep architecture or inflammatory biomarker levels that was initiated prior to study enrollment and is unrelated to the study treatment program, including:\n\n   * Benzodiazepines or z-drugs (zopiclone, zolpidem)\n   * Antipsychotic medications\n   * Systemic corticosteroids\n   * Immunosuppressive agents\n   * Melatonin or melatonin receptor agonists Medications initiated as part of the Day Hospital treatment program after enrollment will be documented and included as covariates in statistical analyses and do not constitute an exclusion criterion.\n8. Presence of an active somatic condition at the time of enrollment requiring acute inpatient medical treatment (e.g., severe electrolyte imbalance requiring intravenous correction, acute cardiac arrhythmia) that would preclude safe participation in the Day Hospital Program\n9. Physical or cognitive inability to cooperate with home polysomnography device placement or self-report questionnaire completion, as judged by the treating child and adolescent psychiatrist\n10. Simultaneous participation in another interventional clinical trial that could influence sleep parameters, nutritional status, inflammatory markers, or psychiatric outcomes.\n11. Absence of written informed consent from parent or legal guardian, or absence of written assent from the participant","10 Years",{"count":7,"type":23},"The purpose of this observational study is to systematically evaluate how a 12-month multimodal psychiatric treatment program affects sleep quality, inflammatory and hormonal biomarkers, eating disorder psychopathology, and health-related quality of life in adolescent girls (aged 10-18 years) diagnosed with anorexia nervosa.\n\nThe main questions it aims to answer are:\n\n* Do adolescent girls with anorexia nervosa have measurable changes in sleep patterns (total sleep time, sleep efficiency, REM sleep, deep sleep) compared to age- and sex-matched published values, and do these improve after 12 months of psychiatric treatment?\n* Are specific body markers (like NLR, CRP, vitamin D, and lipid profile) linked to how severe sleep problems, eating disorder symptoms, and treatment results are in this group?\n* To assess these outcomes, researchers will compare participants' baseline measurements to their own 12-month follow-up measurements to determine whether multimodal psychiatric treatment produces clinically meaningful improvements in sleep architecture, biomarker profiles, psychopathology, psychological flexibility, and quality of life.\n\nParticipants will:\n\n* Take-home sleep recordings with a wireless device (NOX A1) in their usual environment at the start and after 12 months of treatment.\n* Complete validated self-report questionnaires assessing sleep quality (PSQI), daytime sleepiness (ESS-CHAD for children and adolescents), eating disorder symptoms (EDE-Q), depression, anxiety, and stress (DASS-21), psychological flexibility (AFQ-Y8), and health-related quality of life (KIDSCREEN-52) at baseline and 12-month follow-up.\n* Give blood samples at the start and after 12 months for testing of inflammation markers, hormone levels, lipids, and anthropometric measurements.\n* Take part in a Day Hospital Program at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia, which includes Acceptance and Commitment Therapy, Cognitive Behavioral Therapy, individual counselling, family work, and medication if needed.",[30],[30,400,401,402,403,404,405],"Sleep Quality","Adolescents, Female","Eating Behaviour","Mental Health","Quality of life","Inflammatory markers","2026-06-08",{"date":408,"type":35},"2026-06-12",{"date":410,"type":23},"2026-05-30",{"date":412,"type":23},"2029-12-31",{"name":414,"class":42},"University of Split, School of Medicine",{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":122,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":43},"100424724","relapse-prevention-and-changing-habits-in-anorexia-nervosa-100424724","NCT04810624","Relapse Prevention and Changing Habits in Anorexia Nervosa","Optimizing Relapse Prevention and Changing Habits in Anorexia Nervosa","REACH+","Inclusion Criteria:\n\n* Diagnosis of Anorexia Nervosa at hospital admission\n* Medically Stable\n* Internet capability with videoconferencing\n* Weight restored (BMI \\> 19 kg\u002Fm2) at New York State Psychiatric Institute\n\nExclusion Criteria:\n\n* Current substance use or other comorbid disorder requiring specialized treatment\n* Pregnancy\n* Imminent risk of suicide\n* Serious medical illness\n* Daily psychotropic medication other than antidepressants (medications that are known effect weight are exclusionary, i.e. stimulants, olanzapine, mirtazapine)\n* Participation in outside psychotherapy or structured treatment program (support groups will be allowed). Individuals who are discharged on medications would need to have a non-study psychiatrist.",{"count":424,"type":23},60,[26],"This study aims to optimize a treatment package for the relapse prevention treatment of AN. In the Preparation Phase, we examined accessibility and feasibility of the treatment package.\n\nIn the current Optimization Phase, we will identify which components of treatment contribute to positive outcomes after acute hospitalization. We will carefully evaluate maintenance of remission, measured by rate of weight loss and end-of-trial status.",[30],"2026-05-28",{"date":430,"type":35},"2026-06-01",{"date":432,"type":35},"2021-06-21",{"date":434,"type":23},"2027-06-01",{"name":143,"class":42},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":280,"minAge":304,"maxAge":152,"enrollmentInfo":444,"targetDuration":4,"studyType":24,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":461,"locationsCount":4},"100561684","fecal-microbiota-transplant-for-anorexia-nervosa-100561684","NCT06593366","Fecal Microbiota Transplant for Anorexia Nervosa","A Pilot Feasibility Randomized Controlled Trial of Fecal Microbiota Transplant for Adolescent Anorexia Nervosa","FMT-AN","Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating\u002Fpurging type) by the primary physician on the ED team, as per standard approach. Study participants will:\n\n* Be 12-17 years-old at time of recruitment\n* Have capacity to consent\n* Be assigned female sex at birth (may be gender diverse)\n* Be active patients in the pediatric ED program at MCH\n* Have a weight that is \\\u003C85% of the Treatment Goal Weight, as determined by the treating physician\n\nExclusion Criteria: Potential study subjects will be excluded due to the following reasons:\n\n* Exposure to antibiotics within two weeks of study randomization\n* Initiation of new probiotics \u002F oral nutritional supplements within two weeks of randomization\n* Active pregnancy\n* Active psychosis or suicidal ideation\n* Other comorbidities that may affect weight or the gut microbiome including celiac disease, inflammatory bowel disease (or other conditions as determined by the study team)",{"count":445,"type":23},20,[26],"The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.",[209,30,206,449,450],"Anorexia in Children","Anorexia",[129,452,453,454,455],"fecal microbiota transplant","pilot study","randomized controlled trial","feasibility","2026-05-22",{"date":458,"type":35},"2026-05-27",{"date":430,"type":23},{"date":434,"type":23},{"name":462,"class":42},"Hamilton Health Sciences Corporation",{"id":464,"slug":465,"hasResults":12,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":4,"eligibilityCriteria":469,"healthyVolunteers":12,"sex":280,"minAge":470,"maxAge":334,"enrollmentInfo":471,"targetDuration":4,"studyType":24,"phases":473,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":43},"100352938","phase-2-transdermal-estrogen-in-women-with-anorexia-nervosa-100352938","NCT03875378","Transdermal Estrogen in Women With Anorexia Nervosa","Transdermal Estrogen for the Treatment of Bone Loss in Women With Anorexia Nervosa","Inclusion Criteria:\n\n1. Female\n2. 19-45 years of age\n3. DSM-5 psychiatric criteria for anorexia nervosa\n4. \\\u003C85% of ideal body weight as defined by the 1983 Metropolitan Life Insurance Height and Weight Tables\n5. Amenorrhea\n6. T-score of \\\u003C -1.0 at spine or hip\n\nExclusion Criteria:\n\n1. Diseases known to affect bone metabolism, including untreated thyroid dysfunction, vitamin D deficiency, Cushing's syndrome, diabetes mellitus or renal insufficiency (eGFR \\\u003C 60)\n2. Personal history of venous or arterial clot\n3. History of stroke or myocardial infarction\n4. History of hypercoagulable disorder\n5. Personal history or history of a first-degree relative with breast cancer\n6. History of hereditary angioedema\n7. Any medication known to affect bone metabolism, including systemic glucocorticoids within three months of the baseline visit, depot medroxyprogesterone within 6 months of the baseline visit, oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit\n8. Bone fracture within the prior 12 months\n9. Serum potassium \\\u003C 3.0 meq\u002FL, serum ALT \\> 3 times the upper limit of normal or Hemoglobin \\\u003C 10 g\u002FdL\n10. Fasting serum triglyceride level \\> 150 mg\u002FdL\n11. Pregnant or breastfeeding (or desiring pregnancy within the next 18 months)\n12. Active substance abuse\n13. Elevated PTH level\n14. 25-OH vitamin D level \\\u003C 20 ng\u002FmL\n15. Low phosphorus level","19 Years",{"count":472,"type":23},66,[57],"Randomized, placebo-controlled study investigating the use of physiologic, transdermal estrogen for low bone mass in adult women with anorexia nervosa.",[30],[477,478],"Bone mineral density","Estrogen","2026-05-14",{"date":481,"type":35},"2026-05-18",{"date":483,"type":35},"2020-08-28",{"date":485,"type":23},"2028-12-31",{"name":487,"class":42},"Pouneh K. Fazeli, MD",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":18,"minAge":496,"maxAge":19,"enrollmentInfo":497,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":43},"100556673","speech-groups-for-children-living-with-a-sibling-who-suffers-from-anorexia-nervosa-100556673","NCT06528158","Speech Groups for Children Living With a Sibling Who Suffers From Anorexia Nervosa","Sibling Group for Children and Teenagers Living With a Sibling Who Suffers From Anorexia Nervosa: a Pilot Acceptability Study","EMA-FRaM","* inclusion criteria : Sibling presenting a DSM (Diagnostic and Statistical Manual)-5 of Mental Disorders diagnosis of AN, and engaged in inpatient or outpatient healthcare\n* exclusion criteria :\n\n  * (1) Opposition from the participant and\u002For from their legal representatives.\n  * (2) Non-fluent French speaker\n  * (3) Clinical presentation not compatible with the group sessions","8 Years",{"count":498,"type":23},24,"Anorexia nervosa (AN) is a complex mental disease with a huge impact on the patient's siblings life and well-being. Based on literature, group interventions for siblings of children suffering from a chronic disease could provide an effective support. A few have been studied, and even fewer exist for siblings of children with AN.",[30],[502,503,504,505,506],"siblings","groups","children","teenagers","acceptability","2026-05-07",{"date":509,"type":35},"2026-05-12",{"date":511,"type":35},"2025-01-02",{"date":513,"type":23},"2026-08-02",{"name":515,"class":42},"University Hospital, Toulouse",{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":280,"minAge":19,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":24,"phases":526,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":537,"leadSponsor":538,"locationsCount":540},"100640622","phase-1-reestablishing-normal-gut-brain-interaction-in-anorexia-nervose-with-normal-gut-microbiota-100640622","NCT07574892","Reestablishing Normal Gut-brain Interaction in Anorexia Nervose With Normal Gut Microbiota","Reestablishing Normal Gut-Brain Interaction in Anorexia Nervosa With Normal Gut Microbiota: Restart","Restart","Inclusion Criteria:\n\nAge 18 years or more Starting outpatient psychotherapy for anorexia nervosa At least one failed qualified treatment attempt\n\nExclusion Criteria:\n\nAge below 18 years BMI below 16 kg\u002Fm2 Significant electrolyte disturbances Other signs of medical instability Presence of systemic disease, Immune deficiency Treated with immune-modulating medication Pregnancy Planning pregnancy Lactations Having undergone abdominal surgery (with the exception of appendectomy, cholecystectomy, caesarian section and hysterectomy) severe psychiatric disease (except anorexia nervosa) Use of probiotics or treatment with antibiotics within 8 weeks prior to study entry.",{"count":525,"type":23},36,[527],"PHASE1","In this pilot study 36 patients with anorexia nervosa (AN) will be randomized to either treatment with psychotherapy as usual (TAU) or TAU plus fecal microbiota transplantation (FMT). The transplantation will be performed when refeeding has started. Patients randomized to TAU+FMT will choose either capsules or gastroscopy as source of FMT. One week after FMT gut microbiota will be collected and analyzed and compared with microbiota composition at baseline. The two groups are then followed during psychotherapy to assess whether it is feasible to give FMT during psychotherapy to study the effects on outcome. In addition, this pilot study is aiming at paving the way for performing larger studies to assess whether FMT improves outcome from psychotherapy when given in combination with psychotherapy in patients with AN.",[30],[229,531,532],"Fecal microbiota transplantation","Psychotherapy","2026-05-05",{"date":535,"type":35},"2026-05-08",{"date":430,"type":23},{"date":141,"type":23},{"name":539,"class":42},"Haukeland University Hospital",4,{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":17,"sex":280,"minAge":19,"maxAge":334,"enrollmentInfo":549,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":550,"conditions":551,"keywords":552,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":559,"locationsCount":43},"100637421","hormonal-and-metabolic-signatures-in-human-hypothalamic-neurons-in-anorexia-nervosa-100637421","NCT07580209","Hormonal And Metabolic Signatures In Human Hypothalamic Neurons In Anorexia Nervosa","HOrmone Profiles and Energy Metabolism Signatures in Hypothalamic-like Neurons Generated From Patients With Anorexia Nervosa","HOPE","Inclusion Criteria:\n\nFemale participants aged 18-45 years (premenopausal) Diagnosis of severe and enduring anorexia nervosa (illness duration ≥7 years, with documented functional impairment and non-response to appropriate treatments) Current BMI ≤18.5 kg\u002Fm² or documented BMI ≤18.5 kg\u002Fm² within the past 12 months Ability to provide informed consent Sufficient proficiency in the study language (German)\n\nFor healthy controls:\n\nFemale participants aged 18-45 years BMI between 18.5 and 24.9 kg\u002Fm² No current or past diagnosis of eating disorders No major psychiatric disorder Ability to provide informed consent\n\nExclusion Criteria:\n\nPregnancy or breastfeeding Severe medical comorbidities affecting metabolic or central nervous system function (e.g., uncontrolled endocrine, hepatic, renal, or cardiovascular diseases) Current psychosis or acute suicidality Current serious non-suicidal self-injury Substance dependence Use of medications that substantially alter metabolic or endocrine function (including high-dose systemic corticosteroids, hormonal contraceptives, or psychotropic medications such as antidepressants, antipsychotics, mood stabilizers, or anxiolytics) Positive status for HIV, hepatitis B (HBV), or hepatitis C (HCV) Intellectual disability impairing the ability to provide informed consent Insufficient proficiency in the study language",{"count":103,"type":23},"The goal of this observational study is to investigate cellular mechanisms of neuroendocrine and metabolic signaling in adult women with anorexia nervosa (AN) compared to healthy controls. The primary purpose is to understand how hypothalamic-like neurons derived from patient samples respond to metabolic hormones and regulate energy homeostasis.\n\nThe main questions it aims to answer are:\n\nDo hypothalamic-like neurons derived from individuals with AN show altered responsiveness to key metabolic hormones compared to neurons derived from healthy controls? Are there differences in cellular metabolism, gene expression profiles, and neuronal activity that reflect disease-relevant neuroendocrine dysfunction? Researchers will compare patient-derived cellular models from individuals with AN to those generated from matched healthy control participants to determine whether differences in hormone responsiveness, metabolic function, and neuronal signaling can be identified.\n\nParticipants will:\n\nAttend a single study visit at a recruiting clinical site Provide a small peripheral blood sample Undergo basic clinical assessment and anthropometric measurements Collected samples will be coded at the recruiting sites and transferred to a central research laboratory, where they will be used to generate induced pluripotent stem cells (iPSCs) and differentiate them into hypothalamic-like neurons. All experimental analyses are conducted in vitro and do not involve any intervention or treatment administered to participants.",[30],[30,252,553,554],"Hypothalamus","Neuroendocrinology",{"date":509,"type":35},{"date":557,"type":35},"2026-04-30",{"date":141,"type":23},{"name":560,"class":42},"Maria Miletta",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":18,"minAge":569,"maxAge":19,"enrollmentInfo":570,"targetDuration":4,"studyType":24,"phases":571,"briefSummary":573,"conditions":574,"keywords":576,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":580,"leadSponsor":582,"locationsCount":43},"100639620","phase-3-pediatric-prolonged-release-melatonin-for-sleep-disturbances-in-children-and-adolescents-with-anorexia-nervosa-melsom-anorexia-100639620","NCT07576764","Pediatric Prolonged-Release Melatonin for Sleep Disturbances in Children and Adolescents With Anorexia Nervosa (MELSom-ANOREXIA)","Efficacy of Pediatric Prolonged-Release Melatonin (PedPRM) Treatment in Children and Adolescents With Impaired Sleep and Anorexia Nervosa (AN)","MELSomAnorexia","INCLUSION CRITERIA\n\nParticipants aged 6 to 18 years, inclusive, with a diagnosis of Anorexia Nervosa (AN) according to DSM-5 criteria Presence of a sleep problem for at least 1 month, defined as ≤ 6 hours of continuous sleep and\u002For ≥ 0.5 hours sleep latency from lights-off on 3 out of 5 nights, based on participant report (with or without parental assistance according to age), confirmed at D0 by 2-week sleep diary No response to at least 4 weeks of sleep hygiene Negative pregnancy test at baseline, prior to randomization, for female participants of childbearing potential Women of childbearing potential must agree to use a highly effective method of contraception during the study treatment period and for at least 4 weeks after the last dose of study treatment Written informed consent obtained in accordance with the participant's legal status and applicable regulations Affiliation to a social security system or equivalent\n\nEXCLUSION CRITERIA\n\nKnown diagnosis of another significant sleep disorder (e.g. moderate to severe sleep apnea) Use of prohibited medication (z-drugs, melatonin agonist, benzodiazepine, phenylpiperazine class, clomethiazole) or melatonin within 2 weeks prior to screening Declared allergy to melatonin, lactose, or any excipient included in the therapeutic units Pregnant or breastfeeding female participants Unresponsiveness to previous prolonged-release melatonin within the 2 years prior to the study Start of cognitive behavioural therapy (CBT) targeting sleep disturbances or mood disorders within 6 weeks before study inclusion Trans-meridian travel (\\> 2 time zones) within the month before the start of the study Patient under legal protection regimen","6 Years",{"count":356,"type":23},[572],"PHASE3","Sleep disturbances are reported by more than 50% of patients with Anorexia Nervosa (AN) and are associated with increased AN severity, psychiatric comorbidities, and poorer quality of life. To date, no pharmacological treatment has been approved or recommended for sleep disorders in children and adolescents with AN. Many drugs are currently prescribed off-label for their sedative side effects, without proven safety or efficacy in this population.\n\nPediatric prolonged-release melatonin (PedPRM, Slenyto®) is the only melatonin formulation approved by the European Medicines Agency (EMA) for chronic insomnia in children aged 2 to 18 years with neurodevelopmental disorders. Its excellent safety profile, absence of tolerance, and long-acting formulation make it a prime candidate for treating sleep disturbances in children and adolescents with AN.\n\nMELSom-ANOREXIA is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb trial. Its primary objective is to assess the efficacy of PedPRM compared to placebo in improving Total Sleep Time (TST) in children and adolescents aged 6 to 18 years with AN and impaired sleep.\n\nParticipants are randomized into two groups: the experimental group receives PedPRM (2 mg or 5 mg depending on response at Day 22) and the control group receives a matching placebo, both administered 0.5 to 1 hour before habitual bedtime for 13 weeks. Sleep is assessed by Sleep Diary and actigraphy. Secondary outcomes include other sleep parameters, AN severity (BMI, EDI-2, EDE-Q), associated symptoms (anxiety, depression, physical activity, executive function, emotionality), and quality of life. Melatonin secretion profiles and specific subgroups (ASD traits, early-onset AN) are also explored.\n\nThe study includes a 2-week run-in period (D-14 to D0) for baseline sleep assessment, followed by 13 weeks of treatment, with visits at D0, D22, and D93. A total of 120 participants will be enrolled across 7 French pediatric psychiatry centers over 24 months.",[30,575],"Sleep Disorders in Children",[128],"2026-05-04",{"date":535,"type":35},{"date":343,"type":23},{"date":581,"type":23},"2029-01-01",{"name":583,"class":42},"Assistance Publique Hopitaux De Marseille",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":18,"minAge":101,"maxAge":334,"enrollmentInfo":591,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":237},"100600489","neural-correlates-of-autistic-individuals-with-anorexia-nervosa-100600489","NCT07098156","Neural Correlates of Autistic Individuals With Anorexia Nervosa","Neuroanatomical Differences Associated With Anorexia Nervosa and Masking Behaviour in Autistic Individuals","Inclusion Criteria:\n\nHealthy Autistic Individuals (Autistic Controls) must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an Autism Quotient (AQ-10) score of ≥6)\n* Be able to provide informed consent for the study\n* Be able to read, understand and respond to questionnaires in English\n* Have no history of an eating disorder\n* Willing to have an MRI scan in Aberdeen\n\nAutistic Individuals with anorexia nervosa must:\n\n* Be aged 25-45 years\n* Be Autistic (clinically diagnosed and\u002For have an AQ-10 score of ≥6)\n* Be able to provide informed consent to the study\n* Be able to read, understand and respond to questionnaires in English\n* Have a diagnosis of anorexia nervosa or a body mass index of \\\u003C18.5\n* Willing to have an MRI scan in Aberdeen\n\nExclusion Criteria:\n\nIndividuals are not eligible for the study if they:\n\n* Are aged \\\u003C25 or \\>45 years\n* Are not Autistic or not clinically diagnosed as Autistic and have an AQ-10 score of \\\u003C6\n* Are diagnosed with an eating disorder other than anorexia nervosa\n* Have a history of brain injury (e.g., stroke)\n* Be unable to provide informed consent for the study\n* Have contraindications to MRI scanning, such has implantable cardiac devices\n* Are unable to read, understand and respond to questionnaires in English\n* As participants will need to consent to the study and complete questionnaires by themselves, individuals with intellectual disability will be excluded from this study",{"count":154,"type":23},"Masking is a behaviour or strategy used by many Autistic people to appear non-Autistic and blend in with a neurotypical society. The goal of this observational study is to understand the relationship between masking, anorexia nervosa symptoms and brain structure in Autistic people. The main questions this study aims to answer are:\n\n* Do Autistic individuals with anorexia nervosa show differences in structure or function of the brain relation to Autistic individuals without anorexia nervosa?\n* Do Autistic individuals with anorexia nervosa display higher levels of masking than Autistic individuals without anorexia nervosa?\n* Are there indeed relationships between levels of masking, anorexia nervosa symptoms and brain structure in Autistic people?\n\nResearchers will compare Autistic people without anorexia nervosa to Autistic people with anorexia nervosa to see if there are differences between groups. Participants will:\n\n* Complete a series of questionnaires focused on eating disorder symptoms, autistic traits, autistic masking and psychological well-being\n* Undergo an MRI scan at the Aberdeen Royal Infirmary",[594,30],"Autism",[596,597],"MRI","Magnetic Resonance Imaging",{"date":533,"type":35},{"date":600,"type":35},"2025-07-15",{"date":602,"type":23},"2026-07-31",{"name":604,"class":42},"University of Aberdeen",{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":609,"acronym":610,"eligibilityCriteria":611,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":24,"phases":615,"briefSummary":616,"conditions":617,"keywords":618,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":624,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":43},"100528867","improving-the-treatment-of-anorexia-nervosa-in-children-through-virtual-reality-body-exposure-100528867","NCT06166355","Improving the Treatment of Anorexia Nervosa in Children Through Virtual Reality Body Exposure","EOAN-VR-ABM","Inclusion Criteria:\n\n* Patients with a primary diagnosis of anorexia nervosa (DSM-V)\n* Patients below 14 years old\n* Patients with BMI \\\u003C18.5\n* Subsyndromal patients will also be included\n\nExclusion Criteria:\n\n* Visual deficits\n* Epilepsy or neuroleptic medication\n* Psychotic disorder\n* Bipolar disorder\n* Medical complications\n* Pregnancy\n* Clinical cardiac arrhythmia","14 Years",{"count":614,"type":23},108,[26],"The age of onset of anorexia nervosa has been progressively decreasing in recent years. Also, the prevalence rates of childhood anorexia in many countries have grown significantly. This increase was already observed before the COVID-19 pandemic, but the confinements and the stress derived from them have caused this increase to accelerate. As in adolescent and adult patients, in childhood anorexia some of the core signs and symptoms are an extreme fear of gaining weight and avoidance of food. The consequences of the early-onset of anorexia can be very important since the maturation of the organism is more incomplete in children than in adolescents. Weight loss can have very severe consequences, since in children the percentage of body fat is lower. On the other hand, hormonal disorders derived from food deprivation also have very severe consequences for the development of different organs. General physical development and growth can be affected, with consequences such as not being able to reach normal height. The research carried out to date on the efficacy of treatments for childhood anorexia is very scarce. There are no specific treatment strategies or settings for children with anorexia, and little research has been done to tailor treatment for younger patients. Given the need to explore new treatments for anorexia nervosa specifically aimed at children, the objective of this project is to develop a program to carry out exposure to one's own body through virtual reality, gradually, with progressive increases in size until achieving a healthy weight. In the virtual exposure, patients will observe the image of an avatar in a mirror for the time necessary in each session to produce the reduction of the anxiety response. The avatars that will be developed for this purpose will have a physical constitution corresponding to children under 14 years of age, and physical proportions equivalent to those of each patient. The positive results obtained with a previous version of this treatment originally developed for adolescents and adults suggest that its adaptation to children can open new ways for exploring effective treatments for childhood anorexia.",[30],[619,620,621,622,623],"Attentional Bias","Virtual Reality","Eye-Tracking","Body exposure procedure","Attentional bias modification training",{"date":535,"type":35},{"date":626,"type":35},"2024-07-01",{"date":628,"type":23},"2026-12-30",{"name":630,"class":42},"University of Barcelona",{"id":632,"slug":633,"hasResults":12,"nctId":634,"briefTitle":635,"officialTitle":636,"acronym":637,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":639,"enrollmentInfo":640,"targetDuration":4,"studyType":24,"phases":641,"briefSummary":642,"conditions":643,"keywords":648,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":659,"completionDateStruct":661,"leadSponsor":663,"locationsCount":43},"100531301","targeting-social-function-in-anxiety-and-eating-disorders-100531301","NCT06198023","Targeting Social Function in Anxiety and Eating Disorders","Targeting Social Function to Improve Outcomes in Anxiety and Eating Disorders","SF","Inclusion Criteria:\n\n* In the past 12 months, has met DSM-5 criteria met for an eating disorder (Anorexia Nervosa, Atypical Anorexia Nervosa, Bulimia Nervosa, Avoidant-Restrictive Food Intake Disorder, or Other Specified Feeding or Eating Disorder) and\u002For an anxiety disorder (Generalized Anxiety Disorder, Social Anxiety Disorder)\n* Between the ages of 18-30\n\nExclusion Criteria:\n\n* Current inpatient or residential treatment\n* Medical instability or safety\u002Fsuicide risk as determined by the PI","30 Years",{"count":424,"type":23},[26],"Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task.\n\nParticipants will:\n\n* attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks\n* complete a pre-intervention assessment with questionnaires\n* attend eight sessions of their assigned treatment group over the course of 12 weeks\n* complete three virtual follow-up assessments 4, 8, and 12 months from their baseline\n* attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks\n\nResearchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if\n\n* patients can be treated effectively with education alone or if an interactive group component produces additional benefits\n* cognitive and behavioral task performance are associated with recovery or illness state.",[252,30,253,644,645,255,646,647],"Atypical Anorexia Nervosa","Purging (Eating Disorders)","Social Anxiety Disorder","Generalized Anxiety Disorder (GAD)",[649,650,651,652,653,654,655,656],"social function","social cognition","social processing","psychoeducation","group therapy","group intervention","art therapy","social anxiety","2026-04-28",{"date":533,"type":35},{"date":660,"type":35},"2024-02-28",{"date":662,"type":23},"2028-09",{"name":664,"class":42},"University of Texas Southwestern Medical Center"]